NCT00219141

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 460 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.

Conditions

• Hypertension
• Left Ventricular Hypertrophy
• Overweight

Interventions

Type	Name	Description
DRUG	Aliskiren 150/300 mg	Aliskiren 150 mg tablets
DRUG	Losartan 50/100 mg	Losartan 50 or 100 mg capsules
DRUG	Aliskiren placebo	Aliskiren 150 mg placebo tablet
DRUG	Losartan 50/100 mg placebo	Losartan 50/100 mg placebo capsules

Timeline

• Start date: 2005-10-01
• Primary completion: 2007-11-01
• Completion: 2007-11-01
• First posted: 2005-09-22
• Last updated: 2011-05-26
• Results posted: 2011-05-10

Locations

9 sites across 9 countries: United States, Argentina, Colombia, Finland, Germany, Italy, Russia, Spain, Sweden